{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:32:56Z","timestamp":1789151576191,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K09729"],"award-info":[{"award-number":["23K09729"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vhri.2025.101511","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:18:13Z","timestamp":1761236293000},"page":"101511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Economic Impact of Self-Injected Biologics for Rheumatoid Arthritis in Japan: A Propensity Score-Matched Analysis From a Public Healthcare Payer Perspective"],"prefix":"10.1016","volume":"53","author":[{"given":"Kazuhiko","family":"Takahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Akutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2025.101511_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.35772\/ghm.2019.01011","article-title":"Population aging in Japan: policy transformation, sustainable development goals, universal health coverage, and social determinates of health","volume":"1","author":"Nakatani","year":"2019","journal-title":"Glob Health Med"},{"issue":"5","key":"10.1016\/j.vhri.2025.101511_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190392","article-title":"Healthcare costs for the elderly in Japan: analysis of medical care and long-term care claim records","volume":"13","author":"Akiyama","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vhri.2025.101511_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0280311","article-title":"Social burden of three major diseases in Japan: a time trend and future projections using the comprehensive cost of illness method","volume":"18","author":"Hirata","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vhri.2025.101511_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"issue":"10","key":"10.1016\/j.vhri.2025.101511_bib5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.23512","article-title":"Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis","volume":"70","author":"Hresko","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.vhri.2025.101511_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/mr\/road020","article-title":"Unincreased mortality of patients with early rheumatoid arthritis compared to the general population in the past 17 years: analyses from the IORRA cohort","volume":"34","author":"Sugitani","year":"2024","journal-title":"Mod Rheumatol"},{"issue":"7","key":"10.1016\/j.vhri.2025.101511_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study","volume":"20","author":"Kato","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"10.1016\/j.vhri.2025.101511_bib8","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/medicina59101878","article-title":"Elderly-onset rheumatoid arthritis: characteristics and treatment options","volume":"59","author":"Pavlov-Dolijanovic","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.vhri.2025.101511_bib9","series-title":"Requirements and Precautions for Home Self-Administration of Injectable Medications Under the Japanese Health Insurance System","year":"2005"},{"issue":"11","key":"10.1016\/j.vhri.2025.101511_bib10","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/apt.16927","article-title":"Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease","volume":"55","author":"Bergqvist","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.vhri.2025.101511_bib11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2018.07.137","article-title":"Is contraceptive self-injection cost-effective compared to contraceptive injections from facility-based health workers? Evidence from Uganda","volume":"98","author":"Di Giorgio","year":"2018","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.vhri.2025.101511_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14397595.2016.1205799","article-title":"Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan","volume":"27","author":"Tanaka","year":"2017","journal-title":"Mod Rheumatol"},{"issue":"34","key":"10.1016\/j.vhri.2025.101511_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22340","article-title":"Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT","volume":"22","author":"Brown","year":"2018","journal-title":"Health Technol Assess"},{"issue":"4","key":"10.1016\/j.vhri.2025.101511_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jval.2017.01.005","article-title":"Cost-effectiveness of TNF-blocker injection spacing for patients with established rheumatoid arthritis in remission: an economic evaluation from the spacing of TNF-blocker injections in rheumatoid arthritis trial","volume":"20","author":"Vanier","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2025.101511_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/mr\/roac160","article-title":"Socioeconomic impact of treatment with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis","volume":"34","author":"Yamanaka","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.vhri.2025.101511_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12913-025-12908-1","article-title":"Health economic evaluation of self-injection of biologics in patients with rheumatoid arthritis using a Japanese real-world web-based survey","volume":"25","author":"Takahata","year":"2025","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.vhri.2025.101511_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/14737167.2023.2160322","article-title":"Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-na\u00efve and biologic-experienced patients with ulcerative colitis in France","volume":"23","author":"Oppe","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.vhri.2025.101511_bib19","first-page":"190","article-title":"Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people","volume":"5","author":"Okada","year":"2022","journal-title":"JMA"},{"issue":"1","key":"10.1016\/j.vhri.2025.101511_bib20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12891-021-04259-9","article-title":"The validity of the claims-based definition of rheumatoid arthritis evaluated in 64 hospitals in Japan","volume":"22","author":"Kubota","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"10.1016\/j.vhri.2025.101511_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.37737\/ace.2.2_33","article-title":"Introduction to applied statistics\u2014chapter 1 propensity score analysis","volume":"2","author":"Yasunaga","year":"2020","journal-title":"Ann Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.vhri.2025.101511_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"ROSENBAUM","year":"1983","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.vhri.2025.101511_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"11","key":"10.1016\/j.vhri.2025.101511_bib24","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.vhri.2025.101511_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"1","key":"10.1016\/j.vhri.2025.101511_bib26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12887-017-0965-y","article-title":"Peripheral venous catheter complications in children: predisposing factors in a multicenter prospective cohort study","volume":"17","author":"Ben Abdelaziz","year":"2017","journal-title":"BMC Pediatr"},{"issue":"1","key":"10.1016\/j.vhri.2025.101511_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.vhri.2025.101511_bib28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.vhri.2025.101511_bib29","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2025.101511_bib30","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s10198-007-0088-8","article-title":"The burden of rheumatoid arthritis and access to treatment: health burden and costs","volume":"8","author":"Lundkvist","year":"2008","journal-title":"Eur J Health Econ"},{"issue":"9","key":"10.1016\/j.vhri.2025.101511_bib31","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3899\/jrheum.121387","article-title":"Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice","volume":"40","author":"Linde","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vhri.2025.101511_bib33","series-title":"An Introduction to the Bootstrap","author":"Efron","year":"1994"},{"issue":"5 Pt 1","key":"10.1016\/j.vhri.2025.101511_bib34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00019053-199813050-00002","article-title":"The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data","volume":"13","author":"Desgagn\u00e9","year":"1998","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.vhri.2025.101511_bib35","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F","article-title":"Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians","volume":"19","author":"Carpenter","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.vhri.2025.101511_bib36","first-page":"83","article-title":"Research on disaster preparedness by migraine patients: awareness of medication notebooks and readiness of medicines","author":"Ishii","year":"2015","journal-title":"J Jpn Soc Pain Clin"},{"issue":"1","key":"10.1016\/j.vhri.2025.101511_bib37","first-page":"2","article-title":"Current status and influencing factors of the stockpiling of regular medicines for disasters in patients with chronic disease","volume":"43","author":"Mitoya","year":"2024","journal-title":"Jpn J Soc Pharm"},{"issue":"6","key":"10.1016\/j.vhri.2025.101511_bib38","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jbspin.2004.01.003","article-title":"Rheumatoid arthritis: direct and indirect costs","volume":"71","author":"Rat","year":"2004","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.vhri.2025.101511_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194130","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -the ANSWER cohort study","volume":"13","author":"Ebina","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vhri.2025.101511_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003160","article-title":"Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"9","author":"Ebina","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.vhri.2025.101511_bib41","series-title":"The 2024 Japanese College of Rheumatology (JCR) Guidelines for the Management of Rheumatoid Arthritis","year":"2024"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925004376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925004376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:23:55Z","timestamp":1777317835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925004376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"alternative-id":["S2212109925004376"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101511","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Impact of Self-Injected Biologics for Rheumatoid Arthritis in Japan: A Propensity Score-Matched Analysis From a Public Healthcare Payer Perspective","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101511"}}